Morolimumab: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
| (9 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
| ⚫ | |||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 458284456 |
||
| image = |
| image = |
||
<!-- Monoclonal antibody data --> |
|||
| ⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = u |
| source = u |
||
| target = [[Rhesus blood group system|RhD]] |
| target = [[Rhesus blood group system|RhD]] |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| Line 21: | Line 20: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 28: | Line 26: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| ⚫ | |||
| UNII = R6LF24NKU4 |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| Line 38: | Line 37: | ||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| ⚫ | |||
| ⚫ | |||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Morolimumab''' is a [[human]] [[monoclonal antibody]] against the human [[Rhesus factor]].<ref> |
'''Morolimumab''' is a [[human]] [[monoclonal antibody]] against the human [[Rhesus factor]].<ref>{{cite journal | title = Proposed International Nonproprietary Names: Morolimumab | journal = WHO Drug Information | volume = 13 | issue = 1 | date = 1991 | page = 45 | url = http://whqlibdoc.who.int/druginfo/INN_1999_list41.pdf | location = Geneva | publisher = World Health Organization }}</ref><ref>{{cite book | vauthors = Pelletier JP, Mukhtar F | chapter = Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies | veditors = Maitta RW |title=Immunologic Concepts in Transfusion Medicine |date=2020 |publisher=Elsevier |location=Philadelphia |isbn=978-0-323-67510-9 | doi = 10.1016/B978-0-323-67509-3.00016-0 |page=300 | s2cid = 213508934 }}</ref> |
||
==References== |
==References== |
||
| Line 53: | Line 50: | ||
{{immunosuppressants}} |
{{immunosuppressants}} |
||
{{Monoclonals for immune system}} |
{{Monoclonals for immune system}} |
||
[[Category:Monoclonal antibodies]] |
|||